Fast Itch Relief during Dupilumab Predicts Clinical Efficacy in Bullous Pemphigoid: A Retrospective Cohort Study.

ABSTRACT:

Introduction

Dupilumab has emerged as a promising treatment option for bullous pemphigoid (BP). Rapid identification of responders could avoid the need for additional immunosuppressive treatments that are associated with increased morbidity and mortality.

Methods

To investigate the course of itch as an early indicator of treatment response, data of 12 BP patients treated with dupilumab at the University Hospital of Zurich were retrospectively evaluated. Disease severity was assessed by bullous pemphigoid disease area index (BPDAI) and pruritus by a numeric rating scale (NRS, 0-10) at baseline; days 1, 3, 14; months 1, 2; and the last follow-up.

Results

A total of 8/12 patients (67%) had complete response, and 4/12 patients (33%) had partial response during dupilumab t

SUBMITTER: Thevan J 

PROVIDER: S-EPMC11651321 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature